Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14215173
Abstract: Simple Summary Management of hepatocellular carcinoma is a rapidly evolving field, with atezolizumab-bevacizumab recently becoming standard of care after showing survival benefit over sorafenib. However, all clinical trials evaluating drugs approved in the second line… read more here.
Keywords: immunotherapy; progression; patients advanced; following progression ... See more keywords